全文获取类型
收费全文 | 766篇 |
免费 | 42篇 |
国内免费 | 35篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 68篇 |
妇产科学 | 3篇 |
基础医学 | 77篇 |
口腔科学 | 28篇 |
临床医学 | 106篇 |
内科学 | 151篇 |
皮肤病学 | 22篇 |
神经病学 | 15篇 |
特种医学 | 184篇 |
外科学 | 34篇 |
综合类 | 25篇 |
预防医学 | 35篇 |
眼科学 | 14篇 |
药学 | 37篇 |
中国医学 | 1篇 |
肿瘤学 | 38篇 |
出版年
2024年 | 1篇 |
2023年 | 1篇 |
2022年 | 2篇 |
2021年 | 8篇 |
2020年 | 3篇 |
2019年 | 8篇 |
2018年 | 16篇 |
2017年 | 12篇 |
2016年 | 10篇 |
2015年 | 19篇 |
2014年 | 11篇 |
2013年 | 27篇 |
2012年 | 18篇 |
2011年 | 14篇 |
2010年 | 42篇 |
2009年 | 39篇 |
2008年 | 13篇 |
2007年 | 19篇 |
2006年 | 17篇 |
2005年 | 33篇 |
2004年 | 11篇 |
2003年 | 4篇 |
2002年 | 9篇 |
2001年 | 13篇 |
2000年 | 8篇 |
1999年 | 16篇 |
1998年 | 47篇 |
1997年 | 46篇 |
1996年 | 48篇 |
1995年 | 33篇 |
1994年 | 40篇 |
1993年 | 35篇 |
1992年 | 11篇 |
1991年 | 14篇 |
1990年 | 7篇 |
1989年 | 22篇 |
1988年 | 43篇 |
1987年 | 19篇 |
1986年 | 15篇 |
1985年 | 28篇 |
1984年 | 6篇 |
1983年 | 2篇 |
1982年 | 6篇 |
1981年 | 8篇 |
1980年 | 8篇 |
1979年 | 5篇 |
1978年 | 5篇 |
1977年 | 6篇 |
1976年 | 12篇 |
1975年 | 3篇 |
排序方式: 共有843条查询结果,搜索用时 140 毫秒
91.
GM Repetto ML Guzmán A Puga JF Calderón CP Astete M Aracena M Arriaza T Aravena P Sanz 《Clinical genetics》2009,76(5):465-470
Patients with chromosome 22q11 deletion syndrome exhibit significant phenotypic variability. Epidemiologic data suggest a higher incidence in Hispanics, but limited clinical information is available from Latin-American patients. We describe the clinical features of Chilean patients with 22q11 deletion syndrome and compare their findings with those reported in large European, Japanese and US series. Data were obtained from 208 patients from five medical centers. Mean age at diagnosis was 5.2 years, with a median of 2.3 years. Congenital heart defects were present in 59.6%, lower than other large series that averaged 75.8%. Palate abnormalities were present in 79%, higher than previous reports averaging 56%. Patients with congenital heart disease were diagnosed earlier (median 0.3 years of age) than those without heart defects (median 5.6 years) and had greater mortality attributable to the syndrome (9.8% vs 2.4%, respectively). The differences in frequencies of major anomalies may be due to growing awareness of more subtle manifestations of the syndrome, differences in clinical ascertainment or the presence of modifier factors. These observations provide additional data useful for patient counseling and for the proposal of health care guidelines. 相似文献
92.
93.
94.
95.
96.
D Gómez-Garre P Mu?oz-Pacheco ML González-Rubio P Aragoncillo R Granados A Fernández-Cruz 《British journal of pharmacology》2009,156(8):1218-1227
Background and purpose:
Ezetimibe, a selective inhibitor of intestinal cholesterol absorption, might also suppress inflammatory components of atherogenesis. We have studied the effects of ezetimibe on two characteristics of atherosclerotic plaques (infiltrate and fibrosis) and on expression of inflammatory genes in a rabbit model of accelerated atherosclerosis.Experimental approach:
Femoral atherosclerosis was induced by a combination of endothelial desiccation and atherogenic diet. Animals were randomized to ezetimibe (0.6 mg·kg−1·day−1), simvastatin (5 mg·kg−1·day−1), ezetimibe plus simvastatin or no treatment, still on atherogenic diet. A control group of rabbits received normolipidemic diet.Key results:
Rabbits fed the normolipidemic diet showed normal plasma lipid levels. Either the normolipidemic diet or drug treatment reduced the intima/media ratio (normolipidemic diet: 22%, ezetimibe: 13%, simvastatin: 27%, ezetimibe + simvastatin: 28%), compared with rabbits with atherosclerosis. Ezetimibe also decreased macrophage content and monocyte chemoattractant protein-1 expression in atherosclerotic lesions. Furthermore, ezetimibe reduced the increased activity of nuclear factor κB in peripheral blood leucocytes and plasma C-reactive protein levels in rabbits with atherosclerosis. In THP-1 cells, ezetimibe decreased monocyte chemoattractant protein-1-induced monocyte migration. Importantly, the combination of ezetimibe with simvastatin was associated with a more significant reduction in plaque monocyte/macrophage content and some proinflammatory markers than observed with each drug alone.Conclusions and implications:
Ezetimibe had beneficial effects both on atherosclerosis progression and plaque stabilization and showed additional anti-atherogenic benefits when combined with simvastatin. Its effect on monocyte migration provides a potentially beneficial action, in addition to its effects on lipids. 相似文献97.
Yip Ronald ML Cheung Tommy T So Ho Chan Julia PS Ho Carmen TK Tsang Helen HL Yu Carrel KL Wong Priscilla CH 《Clinical rheumatology》2023,42(8):2013-2027
Clinical Rheumatology - Gout is one of the most common noncommunicable diseases in Hong Kong. Although effective treatment options are readily available, the management of gout in Hong Kong remains... 相似文献
98.
Wilson PM Fazzone W LaBonte MJ Deng J Neamati N Ladner RD 《Molecular cancer therapeutics》2008,7(9):3029-3037
For over 40 years, the fluoropyrimidine 5-fluorouracil (5-FU) has remained the central agent in therapeutic regimens employed in the treatment of colorectal cancer and is frequently combined with the DNA-damaging agents oxaliplatin and irinotecan, increasing response rates and improving overall survival. However, many patients will derive little or no benefit from treatment, highlighting the need to identify novel therapeutic targets to improve the efficacy of current 5-FU-based chemotherapeutic strategies. dUTP nucleotidohydrolase (dUTPase) catalyzes the hydrolysis of dUTP to dUMP and PPi, providing substrate for thymidylate synthase (TS) and DNA synthesis and repair. Although dUTP is a normal intermediate in DNA synthesis, its accumulation and misincorporation into DNA as uracil is lethal. Importantly, uracil misincorporation represents an important mechanism of cytotoxicity induced by the TS-targeted class of chemotherapeutic agents including 5-FU. A growing body of evidence suggests that dUTPase is an important mediator of response to TS-targeted agents. In this article, we present further evidence showing that elevated expression of dUTPase can protect breast cancer cells from the expansion of the intracellular uracil pool, translating to reduced growth inhibition following treatment with 5-FU. We therefore report the implementation of in silico drug development techniques to identify and develop small-molecule inhibitors of dUTPase. As 5-FU and the oral 5-FU prodrug capecitabine remain central agents in the treatment of a variety of malignancies, the clinical utility of a small-molecule inhibitor to dUTPase represents a viable strategy to improve the clinical efficacy of these mainstay chemotherapeutic agents. 相似文献
99.
100.